Many novel<unk> <unk> es and Biologic immunomodulators<unk>  reactions may mimic common ED presentations such as sepsis.
Genetically engineered T cells
CD19–chimeric antigen receptor (CAR)-T cell<unk> 
Monoclonal Antibodies against PD-1 checkpoints
Small-molecule inhibitors
Monoclonal antibodies against cell surface antigens
Antibody-drug conjugates
Immunotoxins
Bispecific T-cell engagers
CD19–chimeric antigen receptor (CAR)-T cell<unk>
Oncologic therapy related adverse events
Decreased cellular immunity which an cause reactivation or new
Paraneoplastic syndromes
Tuberculosis
Post-surgical complications
Sepsis
Intrathecal drug delivery system complications
Fungal infections